Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 13/20 | 0.84 |
| ▸ | SSTR5 | P35346 | 5/20 | 0.84 |
| ▸ | EED | O75530 | 2/20 | 0.84 |
| ▸ | LMNA | P02545 | 2/20 | 0.84 |
| ▸ | GAA | P10253 | 2/20 | 0.84 |
| ▸ | MEN1 | O00255 | 1/20 | 0.84 |
| ▸ | MLNR | O43193 | 1/20 | 0.84 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.84 |
| ▸ | USP2 | O75604 | 1/20 | 0.84 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.84 |
| ▸ | EGFR | P00533 | 1/20 | 0.84 |
| ▸ | HLA-A | P04439 | 1/20 | 0.84 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.84 |
| ▸ | TP53 | P04637 | 1/20 | 0.84 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.84 |
| ▸ | LCK | P06239 | 1/20 | 0.84 |
| ▸ | FYN | P06241 | 1/20 | 0.84 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.84 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.84 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.84 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Astemizole SCHEMBL4385 | 0.91 | KCNH2 (1.00) | KCNH2SSTR5EEDLMNAGAA | |
| SCHEMBL2380395 | 0.90 | KCNH2 (0.84) | KCNH2SSTR5EEDLMNAGAA | |
| SCHEMBL10428997 | 0.89 | SSTR5 (0.89) | KCNH2SSTR5EEDLMNAGAA | |
| SCHEMBL22375097 | 0.89 | KCNH2 (0.80) | KCNH2SSTR5EEDLMNAGAA | |
| [3H]-Astemizole SCHEMBL13109223 | 0.89 | KCNH2 (0.89) | KCNH2SSTR5EEDLMNAGAA | |
| [3H]-Astemizole SCHEMBL30412778 | 0.89 | KCNH2 (0.89) | KCNH2SSTR5EEDLMNAGAA | |
| SCHEMBL11480993 | 0.89 | SSTR5 (0.85) | KCNH2SSTR5EEDLMNAGAA | |
| Desmetheylastemizole SCHEMBL1152697 | 0.88 | KCNH2 (1.00) | KCNH2SSTR5EEDLMNAGAA | |
| SCHEMBL9580736 | 0.88 | SSTR5 (0.87) | KCNH2SSTR5EEDLMNAGAA | |
| SCHEMBL11571595 | 0.88 | SSTR5 (0.87) | KCNH2SSTR5EEDLMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018102067-A2 | TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE | Arvinas, Inc. (US) | 2018-06-07 | — | — | WO | disclosed |
| US-20180125821-A1 | TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2018-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180125821-A1 | TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE | CRBN, VHL, UBQLN2 | KCNH2 4854/4885SSTR5 4691/4885EED 2114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.